Nodal dissection in thymic surgery: a narrative review of the evolution of practice and evidence in the era of the 9th edition TNM classification (2000–2025) Authors: Harleen Kaur, Ritu R Gill, Joshua Sonett Published: 2026 ABSTRACT AbstractBackground and ObjectiveLymph node dissection (LND) for thymic epithelial tumors (TETs) has been performed inconsistently due to guidance from heterogeneous definitions of “intentional” versus “incidental” nodal dissection. Persistent variability in the recommendations of the International Thymic Malignancy Interest Group (ITMIG) and the International Association for the Study of Lung Cancer (IASLC), there remains equipoise among surgical teams on nodal dissection during thymic resection. The objective of this narrative review is to synthesize the contemporary evidence on the indications, optimal extent, technical conduct, and oncologic implications of LND in TETs, and to translate that evidence into a pragmatic, risk-adapted protocol to guide clinical practice.MethodsWe performed a focused narrative review covering January 2000 to March 2025. PubMed/MEDLINE, the Cochrane Library, Embase, Scopus, and Web of Science were searched using a Boolean string combining “thymoma OR thymic carcinoma OR thymic neuroendocrine tumor OR thymic epithelial tumor” with “lymphadenectomy OR lymph node dissection OR nodal metastasis”. The search was supplemented by the Japanese Association for Research in the Thymus (JART), European Society of Thoracic Surgeons (ESTS), and Chinese Alliance for Research in Thymoma (ChART) database publications. Inclusion criteria: adult human studies; English; ≥20 patients with TET reporting nodal yield, incidence, or outcomes. Thirty-two studies were retained.Key Content and FindingsNodal incidence varied predictably with histology and stage: <2% in World Health Organization (WHO) type A/AB/B1; 5–15% in B2/B3; 25–32% in thymic carcinoma; 40–50% in thymic neuroendocrine tumor (NET). Tumor size >5 cm, T3–T4 disease, and high-grade histology were independent predictors. Skip metastasis to N2 occurred in 8–10% of thymic carcinomas, most commonly the right paratracheal (4R). LND improved staging accuracy but did not independently improve survival in propensity-matched analyses, reflecting confounding by adjuvant therapy and the role of nodal status as a marker of disease biology.ConclusionsA risk-adapted, approach is recommended: omit LND for clinical T1a thymomas; perform N1 sampling for B2/B3 or T1b–T2 disease; perform systematic N1 + N2 dissection targeted by nodal stations for thymic carcinoma and thymic NET, including the right paratracheal station regardless of laterality. Persistent gaps include the absence of prospective randomized data, heterogeneous definitions of LND, and lack of validated preoperative radiologic predictors. A multinational prospective registry-based trial is warranted.Keywords: Thymic epithelial tumors (TETs), lymph node dissection (LND), TNM 9th edition, mediastinal staging Introduction Thymic epithelial tumors (TETs)—thymomas, thymic carcinomas, and thymic neuroendocrine tumors (NETs)—are the most common primary neoplasms of the anterior mediastinum and span an unusually wide biological spectrum, from indolent encapsulated thymomas to aggressive carcinomas with early hematogenous and lymphatic dissemination (1-3). For most solid-organ malignancies, regional lymph node assessment is a non-negotiable component of cancer surgery; in thymic surgery, in contrast, the role of lymph node dissection (LND) has remained one of the most contested questions in thoracic oncology (4-6). International surveys of thoracic surgeons performed after the introduction of the 8th-edition TNM classification documented marked variability between regions and between minimally invasive and open programs: N1 dissection was performed in approximately half of thymoma resections and two-thirds of thymic carcinoma resections, while N2 dissection was performed in only one-fifth of thymoma resections (4). Differences between the recommendations of the International Thymic Malignancy Interest Group (ITMIG) and the International Association for the Study of Lung Cancer (IASLC), and between the Japanese Association for Research in the Thymus (JART), Chinese Alliance for Research in Thymoma (ChART), and European Society of Thoracic Surgeons (ESTS) thymic working groups, have entrenched this heterogeneity (7-9). The implementation of the 9th-edition IASLC/UICC TNM classification in 2025 introduces a refined T-category that incorporates a 5-cm size cutoff (T1a ≤5 cm; T1b >5 cm) and reclassifies lung and phrenic-nerve invasion as T2 (10,11). Crucially, however, the N descriptors are unchanged. Surgeons therefore inherit a system that is more granular for the primary tumor but provides no new guidance on which nodes to harvest, how many constitute an adequate dissection, or whether nodal information should change adjuvant decision-making (10-12). Existing narrative reviews have summarized the descriptive epidemiology of nodal involvement (13,14) but have not, to our knowledge, integrated the 9th-edition update with the JART/ChART/ITMIG registry data, addressed the documented “survival paradox” critically, or proposed a radiology-anchored decision framework for the very common clinical situation in which definitive histology is not available before resection. This review was therefore designed to answer four specific questions: What is the contemporary incidence and anatomic distribution of nodal metastasis across TET subtypes? What is the contemporary incidence and anatomic distribution of nodal metastasis across TET subtypes? Which preoperative variables—including radiological and metabolic parameters—predict nodal involvement? Which preoperative variables—including radiological and metabolic parameters—predict nodal involvement? What is the optimal extent of LND for each risk stratum, and what nodal yield should be considered adequate? What is the optimal extent of LND for each risk stratum, and what nodal yield should be considered adequate? Does intentional LND independently improve oncologic outcomes, and if not, why? Does intentional LND independently improve oncologic outcomes, and if not, why? By integrating registry-level data with single-center series and recent 9th-edition staging publications, we propose a pragmatic, radiology-anchored, risk-adapted algorithm intended for routine surgical practice. We present this article in accordance with the Narrative Review reporting checklist (available at https://med.amegroups.com/article/view/10.21037/med-2026-1-0007/rc). Methods Search strategy PubMed/MEDLINE, the Cochrane Library, Embase, Scopus, and Web of Science were searched from January 1, 2000, through March 31, 2025. The Boolean string was: (“thymoma” OR “thymic carcinoma” OR “thymic neuroendocrine tumor” OR “thymic epithelial tumor” OR “TET”) AND (“lymphadenectomy” OR “lymph node dissection” OR “nodal metastasis” OR “nodal involvement” OR “mediastinal staging”) AND (“TNM” OR “staging” OR “survival” OR “outcomes”) The electronic search was supplemented by hand-searching of: (I) JART thymic-database publications; (II) ESTS thymic working-group reports; (III) ChART consortium publications; (IV) ITMIG/IASLC consensus statements; and (V) reference lists of included studies. The search strategy is summarized in Table 1. Table 1Search strategy summaryItemsSpecificationDate of searchInitial search: October 1, 2025; Updated search: February 28, 2026Databases and other sources searchedPubMed/MEDLINE, Cochrane Library, Embase, Scopus, Web of Science; supplemented by JART, ESTS, ChART thymic database publications and ITMIG/IASLC consensus documents; and reference lists of included studiesSearch terms used(“thymoma” OR “thymic carcinoma” OR “thymic neuroendocrine tumor” OR “thymic epithelial tumor” OR “TET”) AND (“lymphadenectomy” OR “lymph node dissection” OR “nodal metastasis” OR “nodal involvement” OR “mediastinal staging” AND (“TNM” OR “staging” OR “survival” OR “outcomes”)TimeframeJanuary 2000–March 2025Inclusion and exclusion criteriaInclusion: adult, English, ≥20 patients, reporting nodal yield/incidence/outcomesExclusion: case reports <20 patients, abstracts only, non-human studies, duplicate cohorts, editorials/lettersSelection processTwo reviewers (H.K. and R.R.G.) independently screened titles and abstracts against the predefined inclusion and exclusion criteria. Full-text articles were retrieved for all potentially eligible studies and assessed independently by the same two reviewers. Discrepancies were resolved by discussion and consensus; when consensus could not be reached, the senior author (J.S.) adjudicated. All retained studies were confirmed by all three authors before final inclusionAdditional considerationsHand-searching of reference lists and 9th-edition TNM Staging Project publications (2023–2025)ChART, Chinese Alliance for Research in Thymoma; ESTS, European Society of Thoracic Surgeons; IASLC, International Association for the Study of Lung Cancer; ITMIG, International Thymic Malignancy Interest Group; JART, Japanese Association for Research in the Thymus; TET, thymic epithelial tumor; TNM, tumor-node-metastasis. Search strategy summary ChART, Chinese Alliance for Research in Thymoma; ESTS, European Society of Thoracic Surgeons; IASLC, International Association for the Study of Lung Cancer; ITMIG, International Thymic Malignancy Interest Group; JART, Japanese Association for Research in the Thymus; TET, thymic epithelial tumor; TNM, tumor-node-metastasis. Inclusion and exclusion criteria Inclusion criteria: adult human studies; English language; ≥20 patients with histologically confirmed TET; reporting at least one of nodal yield, anatomic distribution of nodal metastasis, or nodal-related oncologic outcome. Exclusion criteria: case reports or series of <20 patients; conference abstracts without subsequent full publication; non-human studies; duplicate-cohort publications (most recent or largest reporting retained); editorials/letters. Selection process and data extraction Data extracted from each study included: country of origin, study design and period, sample size, histologic distribution, T category distribution, proportion undergoing intentional vs. incidental LND, anatomic stations dissected, nodal yield, nodal positivity by histology and T stage, and survival outcomes. Findings were synthesized qualitatively. Results The 9th-edition TNM classification: what is new and what is unchanged The 9th-edition TNM classification, developed by the Thymic Domain of the IASLC Staging and Prognostic Factors Committee from a database of more than 11,000 patients, refines the T category but leaves N and M descriptors unchanged (10,11). T1 is now subdivided by size at a 5-cm cutoff (T1a ≤5 cm; T1b >5 cm). Lung and phrenic-nerve invasion are reclassified from T3 to T2. Stage groupings are unchanged. Although the nodal map itself remains unchanged, the 9th edition provides clearer radiologic and surgical illustrations: N1—perithymic and anterior mediastinal nodes; N2—paratracheal, subcarinal, aortopulmonary window, hilar, jugular, and supraclavicular stations (12). Full descriptors in Table 2. Table 29th-edition AJCC/UICC TNM classification of thymic epithelial tumorsCategoryDefinitionT1Tumor limited to the thymus, with or without encapsulation, OR directly invading mediastinal fat or mediastinal pleura but no other mediastinal structureT1aTumor ≤5 cm in greatest dimensionT1bTumor >5 cm in greatest dimensionT2Tumor directly invades: Pericardium (partial or full thickness) The lung Phrenic nerveT3Tumor directly invades any of the following: Brachiocephalic vein Superior vena cava Chest wall Or extrapericardial Pulmonary arteries or veinsT4Tumor directly invades any of following: Aorta; arch vessels Intrapericardial pulmonary artery or veins Myocardium Trachea EsophagusN0No nodal involvementN1Anterior (perithymic) nodesN2Deep intrathoracic or cervical nodes (paratracheal, subcarinal, aortopulmonary window, hilar, jugular, supraclavicular)M0No metastatic pleural, pericardial, or distant sitesM1aSeparate pleural or pericardial nodule(s)M1bPulmonary intraparenchymal nodule or distant organ metastasisAJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis; UICC, Union for International Cancer Control. 9th-edition AJCC/UICC TNM classification of thymic epithelial tumors AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis; UICC, Union for International Cancer Control. Patterns of nodal dissection in contemporary practice An international web-based cross-sectional survey conducted after implementation of the 8th-edition TNM classification documented substantial variability in nodal dissection (4). N1 dissection was performed in approximately 50% of thymoma resections and 66% of thymic carcinoma resections; N2 dissection was performed in 21% and 41%, respectively. Minimally invasive approaches were infrequently associated with N2 dissection. Regional differences mirror differences in registry inclusion criteria: JART data (higher proportion of thymic carcinoid/NET) report higher pooled nodal positivity than ITMIG/IASLC pooled data, while ChART data (higher proportion of advanced thymic carcinoma) report intermediate values (6-9,15). Incidence and risk factors for nodal metastasis A prospective multicenter Chinese observational study of 275 patients reported nodal metastasis in 2.1% of thymomas, 25% of thymic carcinomas, and 50% of thymic NETs (6). Nodal involvement correlated strongly with high-grade histology and advanced T stage. Positive lymph nodes were identified in only 0.5% of patients with T1–T2 disease compared with 13.3% with T3–T4 disease, with an overall nodal-positivity rate of 17%. These findings are consistent with earlier large-scale Japanese data. A multicenter analysis of 1,320 patients (1990–1994) identified nodal metastasis in 1.8% of thymomas, 26.8% of thymic carcinomas, and 27.5% of thymic carcinoids (7). Local invasion was strongly associated with nodal spread: among thymomas, nodal positivity was 5.6% in invasive vs. 0.3% in non-invasive tumors. Pooled estimates by histology and T stage are summarized in Table 3. Table 3Pooled nodal incidence by histology and T categoryHistology/stagePooled nodal incidenceMost frequent stationsSourceWHO type A<1%Perithymic (N1)Kondo 2003 (7); Fang 2018 (6)WHO type AB/B11–2%Perithymic (N1)Hwang 2018 (8); Clermidy 2021 (17)WHO type B25–7%Perithymic, internal mammary, anterior mediastinalKondo 2003 (7); Hwang 2018 (8)WHO type B310–15%N1 + paratracheal (4R), aortopulmonary windowHwang 2018 (8); Cheufou 2019 (15)Thymic carcinoma25–32%N1 + N2; right paratracheal (4R) frequentFang 2018 (6); Hwang 2018 (8); ITMIG/IASLC (10,11)Thymic NET40–50%Systematic N1 + N2; mediastinal/cervicalFang 2018 (6); Cheufou 2019 (15)T1–T2 (any histology)0.5–3%Perithymic predominantFang 2018 (6); Kondo 2003 (7)T3–T4 (any histology)13–18%N1 + N2; multistation involvementFang 2018 (6); Hwang 2018 (8)IASLC, International Association for the Study of Lung Cancer; ITMIG, International Thymic Malignancy Interest Group; N, node; NET, neuroendocrine tumor; T, tumor; WHO, World Health Organization. Pooled nodal incidence by histology and T category IASLC, International Association for the Study of Lung Cancer; ITMIG, International Thymic Malignancy Interest Group; N, node; NET, neuroendocrine tumor; T, tumor; WHO, World Health Organization. Impact of LND on staging and outcomes A multicenter retrospective study of 1,597 patients evaluated predictors of nodal metastasis and the prognostic implications of LND (8). Intentional LND was performed in approximately 30% of cases. Nodal metastasis was identified in 6.7% of thymomas and 31.8% of thymic carcinomas, with high-grade histology and larger size as significant predictors. pN1 and pN2 disease were associated with significantly worse 10-year freedom from recurrence than pN0, but LND itself, in propensity-matched analysis, did not independently improve long-term recurrence outcomes. This dissociation—the “survival paradox”—is discussed below. Survival implications of nodal involvement A single-center retrospective analysis of 53 patients with thymic carcinoma and thymic NET reported nodal metastasis in 30.2% (15). Lymph node positivity independently predicted worse overall survival; this prognostic effect has been confirmed in larger ITMIG and JART analyses (8-10,16). Yield and morbidity of LND in thymomas In a single-institution cohort study of systematic LND in thymomas (17), nodal dissection was performed in 72% of patients in the systematic-LND era, compared with 5% of a historical control. Nodal metastasis was rare overall (2.8%) and confined to tumors >7 cm or with B2/B3 histology. There was a numerical, but not statistically significant, increase in transient recurrent laryngeal nerve palsy in the systematic-LND cohort. These data illustrate that the morbidity of LND in low risk thymomas is real but modest, and that routine bilateral mediastinal dissection in this population is unlikely to be justified by oncologic gain. Survival data are summarized in Figure 1. Kaplan-Meier survival curves stratified by (A) Masaoka stage; (B) AJCC/UICC TNM stage; (C) nodal involvement (LN− vs. LN+); (D) metastatic involvement (M0 vs. M1+). AJCC, American Joint Committee on Cancer; LN, lymph node; TNM, tumor-node-metastasis; UICC, Union for International Cancer Control. Preoperative radiological prediction of risk and implications for LND Because definitive histology is rarely available before thymic resection, surgical planning must be anchored in preoperative imaging. Computed tomography (CT), magnetic resonance imaging (MRI), and fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) each contribute (18-21). Features that predict invasive histology (and therefore higher nodal risk) include tumor diameter >5 cm; lobulated or irregular contour; loss of mediastinal-fat planes; heterogeneity on contrast-enhanced CT; calcification or necrosis; and elevated 18F-FDG uptake [maximum standardized uptake value (SUVmax) ≥5.0 in most series, with thymic carcinoma typically ≥7.0] (19-21). Radiologically suspicious mediastinal lymphadenopathy (short-axis ≥10 mm, central necrosis, or focal FDG avidity) should prompt pre-resection biopsy of N2 stations or, intra-operatively, targeted dissection rather than reliance on frozen-section sampling alone. This radiology-anchored framework underpins the algorithm in Table 4 and Figure 1. In a presumed-low-risk lesion (≤5 cm, smooth contour, fat planes preserved, SUVmax <3.5), only perithymic tissue is excised. In an intermediate-risk lesion (5–8 cm, lobulated, or SUVmax 3.5–5.0), N1 sampling with intra-operative frozen section is performed, with extension to suspicious N2 stations as indicated. In a presumed-high-risk lesion (>5 cm with infiltrative borders, vascular involvement, calcification, SUVmax >5.0, or radiologically suspicious nodes), systematic N1 + N2 dissection is performed, with the right paratracheal (4R) station included in every case. Table 4Proposed radiology-anchored, risk-adapted protocol for nodal dissectionPreoperative risk stratumImaging featuresPresumed histology/stageRecommended LNDLow≤5 cm; smooth contour; preserved fat planes; homogeneous enhancement; SUVmax <3.5; no nodal diseaseWHO A/AB/B1; T1aPerithymic excision only; no formal LNDIntermediate5–8 cm or lobulated contour or SUVmax 3.5–5.0; no infiltration; no suspicious nodesWHO B2; T1b–T2N1 sampling; intra-operative frozen section; extend to suspicious N2 stationsHigh>5 cm with infiltrative borders, vascular involvement, calcification, or SUVmax >5.0; or radiologically suspicious nodesWHO B3, thymic carcinoma, thymic NET; ≥T2 likelySystematic N1 + N2 dissection ≥10 nodes; include right paratracheal (4R) regardless of lateralityLND, lymph node dissection; N, node; NET, neuroendocrine tumor; SUVmax, maximum standardized uptake value; T, tumor; WHO, World Health Organization. Proposed radiology-anchored, risk-adapted protocol for nodal dissection LND, lymph node dissection; N, node; NET, neuroendocrine tumor; SUVmax, maximum standardized uptake value; T, tumor; WHO, World Health Organization. Discussion The findings of this review confirm the persistent uncertainty surrounding the role and extent of LND in TETs and clarify why that uncertainty has proven so durable. We organize the discussion around five themes. Registry-level concordance and discordance Despite differences in case mix, the JART, ChART, and IASLC/ITMIG datasets agree on the principal axes of nodal risk: histology and T stage (6-11,17). They diverge, however, on absolute nodal incidence and on the apparent prognostic effect of LND. JART data—higher proportion of thymic carcinoid/NET—report higher pooled nodal positivity than ITMIG/IASLC data; ChART data, with a higher proportion of advanced thymic carcinoma, report intermediate values. The fraction of resections in which LND was “intentional” versus “incidental” also differs substantially. This methodological heterogeneity is the single largest barrier to a definitive synthesis of nodal-impact studies. The survival paradox of nodal dissection Across propensity-matched series, pN+ disease is consistently a strong adverse prognostic marker, yet the act of dissecting nodes does not, by itself, translate into a survival advantage (8,16,17). Three non-mutually exclusive mechanisms most plausibly explain this paradox. First, confounding by adjuvant therapy: pN+ patients are systematically referred for adjuvant chemoradiation, attenuating any incremental survival signal attributable to surgery alone. Second, lead-time and stage-migration effects (Will Rogers phenomenon). Third—and most plausibly—nodal positivity is a marker of systemic biological aggressiveness, not a modifiable surgical endpoint. The implication is that the principal value of LND is informational—staging, prognostication, adjuvant decision-making—rather than directly therapeutic. Surgical approach: video-assisted thoracic surgery (VATS), robotic-assisted thoracic surgery (RATS), and open thoracotomy Whether minimally invasive thymectomy can deliver an oncologically equivalent nodal evaluation has become a central operational question (22-25). Older VATS series demonstrated lower N2 yields and a smaller proportion of N2 dissections compared with open thoracotomy, particularly for tumors >5 cm. More recent RATS data report comparable nodal yields to open in tumors up to 5–7 cm and superior visualization of deep N2 stations such as 4R and the aortopulmonary window. For tumors >5 cm with infiltrative borders, vascular contact, or radiologically suspicious nodes, open thoracotomy or sternotomy remains the standard for ensuring oncological safety and complete bilateral mediastinal dissection. Skip metastasis to N2 stations Skip metastasis—N2 disease without N1 disease—has been reported in approximately 8–10% of thymic carcinomas, most often involving the right paratracheal (4R) station (6,7,15,16). This finding is incompatible with a strategy of selective N1-only sampling in thymic carcinoma: roughly one in ten patients with apparently negative N1 disease will harbor occult N2 metastasis if N2 stations are not formally examined. Skip metastasis appears to be uncommon in World Health Organization (WHO) type A–B1 thymomas but should be considered specifically in B3 thymomas, thymic carcinomas, and NETs. The right paratracheal station as an obligatory target Anatomic dissection studies and registry data converge on the right paratracheal (station 4R) as the most frequently involved N2 station in TETs, irrespective of primary tumor laterality (7,11,16). Multiple authors have argued that 4R should be sampled in every thymic carcinoma and NET resection, and biopsied whenever radiologically suspicious in any TET. Failure to evaluate 4R is the single most common reproducible cause of pathologic under staging in thymic carcinoma. Is the 5 cm cutoff sufficient to trigger LND? The 9th-edition T1a/T1b 5 cm cutoff is supported by the IASLC database (10,11). It is, however, necessary but not sufficient as a trigger for LND. Size should be combined with contour, fat-plane preservation, contrast heterogeneity, calcification, and PET avidity to inform the decision. Conclusions Nodal involvement in TETs is driven primarily by histology, T stage, and tumor invasiveness. Selective, risk-adapted LND improves staging accuracy and prognostic precision but has not been demonstrated to independently improve survival in propensity-matched series, most plausibly because nodal positivity is a marker of systemic biological aggressiveness rather than a modifiable surgical endpoint. We propose the following actionable recommendations: For radiologically benign T1a thymomas (≤5 cm; smooth contour; preserved fat planes; SUVmax <3.5), omit formal LND and excise perithymic tissue only; For radiologically benign T1a thymomas (≤5 cm; smooth contour; preserved fat planes; SUVmax <3.5), omit formal LND and excise perithymic tissue only; For B2/B3 thymoma or T1b–T2 disease, perform N1 sampling with intra-operative frozen section; extend to any suspicious N2 station; For B2/B3 thymoma or T1b–T2 disease, perform N1 sampling with intra-operative frozen section; extend to any suspicious N2 station; For thymic carcinoma and thymic NET, perform systematic N1 + N2 dissection targeting ≥10 nodes or/complete N1 and 3 N2 nodal stations (the threshold proposed in expert practice to reliably exclude pN0); For thymic carcinoma and thymic NET, perform systematic N1 + N2 dissection targeting ≥10 nodes or/complete N1 and 3 N2 nodal stations (the threshold proposed in expert practice to reliably exclude pN0); Include the right paratracheal (4R) station in every thymic carcinoma and NET resection, regardless of primary tumor laterality; Include the right paratracheal (4R) station in every thymic carcinoma and NET resection, regardless of primary tumor laterality; Document nodal yield by station in operative and pathology reports; record any deviation with explicit justification. Document nodal yield by station in operative and pathology reports; record any deviation with explicit justification. Limitations of the current evidence base are explicit and important: it is dominated by retrospective single-center series and registry analyses; definitions of “intentional LND” and “adequate yield” vary; prospective randomized data are absent; and thymic NET, the highest-risk subtype, is under-represented in every published cohort. We advocate a multinational prospective registry-based trial with a standardized minimum dataset (nodal stations dissected, count by station, pathologic positivity by station, surgical approach, intra-operative frozen section, complications) and a parallel prospective validation of preoperative radiologic and radiomic predictors. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the Guest Editor (Malgorzata Szolkowska) for “The Series Dedicated to the 15th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2025)” published in Mediastinum. The article has undergone external peer review. Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://med.amegroups.com/article/view/10.21037/med-2026-1-0007/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-2026-1-0007/coif). “The Series Dedicated to the 15th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2025)” was commissioned by the editorial office without any funding or sponsorship. J.S. is a consultant for Medtronic. R.R.G. has a consulting relationship with Icon Inc., Median Inc., Voint Clinical Inc., Johnson & Johnson and Need Inc.; and received travel support from IASLC in the last 24 months. The authors have no other conflicts of interest to declare. References Available at https://med.amegroups.com/article/view/10.21037/med-2026-1-0007/prf Supplementary Materials The article’s supplementary files as